UNIVERSITY OF NOTRE DAME
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1842-11-26
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.nd.edu
Clinical Trials
27
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
The Unique and Combined Effects of Prenatal and Early Childhood Programming on Child Maltreatment: Examining Mechanisms of Change
- Conditions
- Child AbuseIntimate Partner ViolenceSecondary PreventionParenting
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Notre Dame
- Target Recruit Count
- 600
- Registration Number
- NCT06732310
- Locations
- 🇺🇸
University of Notre Dame, Notre Dame, Indiana, United States
🇺🇸University of Wisconsin - Madison, Madison, Wisconsin, United States
Spatial Repellents for Malaria Control
- Conditions
- Malaria
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- University of Notre Dame
- Target Recruit Count
- 2160
- Registration Number
- NCT06122142
- Locations
- 🇺🇬
Catholic Relief Services, Kampala, Uganda
🇺🇬Infectious Disease Research Collaboration, Kampala, Uganda
EaveTubes for Vector Control
- Conditions
- Malaria
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- University of Notre Dame
- Target Recruit Count
- 1870
- Registration Number
- NCT05736679
- Locations
- 🇨🇮
Institut Pierre Richet, Bouaké, Côte D'Ivoire
An Evidence-based Family Support Program for Parents and Children in Palestine: a Theory-based Intervention
- Conditions
- Parent-Child RelationsPsychopathologyViolenceAdolescent
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- University of Notre Dame
- Target Recruit Count
- 900
- Registration Number
- NCT05706376
- Locations
- 🇺🇸
University of NotreDame, Notre Dame, Indiana, United States
Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents
- Conditions
- Suicidal IdeationSelf Harm
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- University of Notre Dame
- Target Recruit Count
- 200
- Registration Number
- NCT05602779
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸University of Notre Dame, South Bend, Indiana, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Nitisinone Shows Promise as Novel Malaria Control Strategy by Making Human Blood Lethal to Mosquitoes
Researchers have discovered that nitisinone, a drug used to treat rare genetic disorders, makes human blood toxic to mosquitoes that transmit malaria, offering a potential new control strategy.